Comparison of quantitative EEG between patients with Alzheimer's disease and those with Parkinson's disease dementia.

Fonseca LC, Tedrus GM, Carvas PN, Machado EC.

Clin Neurophysiol. 2013 Oct;124(10):1970-4. doi: 10.1016/j.clinph.2013.05.001.

Malignant arrhythmia as the first manifestation of Wolff-Parkinson-White syndrome: a case with minimal preexcitation on electrocardiography.

Gungor B, Alper AT.

West Indian Med J. 2013 Sep;62(7):672-4. doi: 10.7727/wimj.2012.084.

[The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].

Titova NV, Katunina EA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(12):105-12. Review. Russian. No abstract available.

Costs of Parkinson's disease in a privately insured population.

Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD.

Pharmacoeconomics. 2013 Sep;31(9):799-806. doi: 10.1007/s40273-013-0075-0.

Epidemiology of complementary and alternative medicine use in patients with Parkinson's disease.

Wang Y, Xie CL, Wang WW, Lu L, Fu DL, Wang XT, Zheng GQ.

J Clin Neurosci. 2013 Aug;20(8):1062-7. doi: 10.1016/j.jocn.2012.10.022. Review.

Bilateral stimulation of the subthalamic nucleus has differential effects on reactive and proactive inhibition and conflict-induced slowing in Parkinson's disease.

Obeso I, Wilkinson L, Rodríguez-Oroz MC, Obeso JA, Jahanshahi M.

Exp Brain Res. 2013 May;226(3):451-62. doi: 10.1007/s00221-013-3457-9.

Apathy in elderly nondemented patients with Parkinson's disease: clinical determinants and relationship to quality of life.

Skorvanek M, Rosenberger J, Gdovinova Z, Nagyova I, Saeedian RG, Groothoff JW, Dijk JP.

J Geriatr Psychiatry Neurol. 2013 Dec;26(4):237-43. doi: 10.1177/0891988713500587.

Changes to saccade behaviors in Parkinson's disease following dancing and observation of dancing.

Cameron IG, Brien DC, Links K, Robichaud S, Ryan JD, Munoz DP, Chow TW.

Front Neurol. 2013 Mar 11;4:22. doi: 10.3389/fneur.2013.00022.

Risk of Parkinson disease after depression: a nationwide population-based study.

Shen CC, Tsai SJ, Perng CL, Kuo BI, Yang AC.

Neurology. 2013 Oct 22;81(17):1538-44. doi: 10.1212/WNL.0b013e3182a956ad.

Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease.

Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A, Farrer MJ.

Mov Disord. 2013 Jun;28(6):811-3. doi: 10.1002/mds.25421.

[Synchrotron radiation-based FTIR microspectroscopy study of 6-hydroxydopamine induced Parkinson's disease cell model].

Zhu HY, Pei X, Wu LY, Qi ZM, Wang YY, Liu B, Zhou HG.

Guang Pu Xue Yu Guang Pu Fen Xi. 2013 Mar;33(3):686-9. Chinese.

The effects of clinical motor variables and medication dosage on working memory in Parkinson's disease.

Moustafa AA, Bell P, Eissa AM, Hewedi DH.

Brain Cogn. 2013 Jul;82(2):137-45. doi: 10.1016/j.bandc.2013.04.001.

Move for Change Part II: a European survey evaluating the impact of the EPDA Charter for people with Parkinson's disease.

Stocchi F, Bloem BR.

Eur J Neurol. 2013 Mar;20(3):461-72. doi: 10.1111/j.1468-1331.2012.03876.x.

Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease.

Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY, Dalaker TO, Kurz MW, Larsen JP, Somme JH, Thompson PM, Tysnes OB, Apostolova LG.

Mov Disord. 2013 Mar;28(3):302-10. doi: 10.1002/mds.25282.

Reduced sympathetic activity in idiopathic rapid-eye-movement sleep behavior disorder and Parkinson's disease.

Sorensen GL, Mehlsen J, Jennum P.

Auton Neurosci. 2013 Dec;179(1-2):138-41. doi: 10.1016/j.autneu.2013.08.067.